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Abstract
Preformed T-cell immune-sensitization should most likely impact allograft outcome during
the initial period after kidney transplantation, since donor-specific memory T-cells may rap-
idly recognize alloantigens and activate the effector immune response, which leads to allo-
graft rejection. However, the precise time-frame in which acute rejection is fundamentally
triggered by preformed donor-specific memory T cells rather than by de novo activated
naïve T cells is still to be established. Here, preformed donor-specific alloreactive T-cell re-
sponses were evaluated using the IFN-γ ELISPOT assay in a large consecutive cohort of
kidney transplant patients (n = 90), to assess the main clinical variables associated with cel-
lular sensitization and its predominant time-frame impact on allograft outcome, and was fur-
ther validated in an independent new set of kidney transplant recipients (n = 67). We found
that most highly T-cell sensitized patients were elderly patients with particularly poor HLA
class-I matching, without any clinically recognizable sensitizing events. While one-year inci-
dence of all types of biopsy-proven acute rejection did not differ between T-cell alloreactive
and non-alloreactive patients, Receiver Operating Characteristic curve analysis indicated
the first two months after transplantation as the highest risk time period for acute cellular re-
jection associated with baseline T-cell sensitization. This effect was particularly evident in
young and highly alloreactive individuals that did not receive T-cell depletion immunosup-
pression. Multivariate analysis confirmed preformed T-cell sensitization as an independent
predictor of early acute cellular rejection. In summary, monitoring anti-donor T-cell sensiti-
zation before transplantation may help to identify patients at increased risk of acute cellular
rejection, particularly in the early phases after kidney transplantation, and thus guide
decision-making regarding the use of induction therapy.
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INTRODUCTION
Outstanding progress has been made in recent decades in assessing the humoral alloimmune
sensitization against donor HLA antigens in kidney transplant patients, and has led to a major
reduction in acute antibody-mediated rejection (ABMR) rates immediately after transplanta-
tion. However, no comparable success has been achieved in the monitoring of the anti-donor
T-cell immune response. As a consequence, acute T-cell mediated rejection (TCMR) is still an
unpredictable event, and this uncertainty negatively affects decision-making in daily
clinical practice.
In fact, there is a considerable inconsistency between what we know from basic immune bi-
ology and what we have learnt from clinical transplantation. It is well accepted that T cells are
key initiators, mediators and effectors of the alloimmune response, thus playing a key role in al-
lograft rejection [1–3]. In fact, alloreactive memory/effector T cells are considered the hallmark
of adaptive immunity since, compared to their naïve counterparts, they are long lived, can be
fully reactivated with less co-stimulation, are less susceptible to novel immunosuppressants
and are directly influenced by heterologous immunity [4–11]. Bearing this in mind, the impact
of pre-transplant T-cell sensitization is more likely to take place during the initial period after
transplantation, since preformed memory T cells are ready to cross-react to donor alloantigens,
ultimately leading to allograft rejection.
Importantly, monitoring T-cell sensitization against donor or even a panel of reactive anti-
gens has been shown to be feasible and reliable using the highly sensitive IFN-γ ELISPOT
assay, and has also been shown to correlate with worse allograft function after kidney trans-
plantation [12–17]. In this regard, our group recently reported the results of a non-randomized
prospective clinical trial [18], monitoring anti-donor cellular alloreactivity in 60 kidney trans-
plant recipients both before and six months after transplantation, with the aim of guiding im-
munosuppression for a calcineurin-inhibitor (CNI)-based or a CNI-free immunosuppressive
regimen [18]. Interestingly, while very low rates of biopsy-proven acute rejection (BPAR) were
obtained in both groups, even among T-cell sensitized individuals receiving CNI drugs a strong
association was observed between 6-month persistence or de novo donor-specific T-cell allor-
eactivity and subclinical TCMR in protocol biopsies, suggesting a specific time-frame relation-
ship between preformed donor-specific memory T cells or de novo alloreactive naïve T cells
and their impact on kidney allograft outcome.
Here, we analyzed the presence of pre-transplant donor-specific T-cell sensitization in a
large consecutive cohort of 90 kidney transplant recipients in whom the type of immunosup-
pression was given without knowing their baseline anti-donor T-cell sensitization status and
the data obtained was further validated in a new independent group of kidney transplant recip-
ients (n = 67). We aimed to investigate the main clinical variables associated with cellular sensi-
tization and the specific post-transplant time-frame in which preformed donor-specific (d-s)
memory T cells may negatively challenge allograft outcome.
MATERIALS ANDMETHODS
Patients
Ninety adult kidney transplant recipients from our Renal Transplant Unit at Bellvitge Univer-
sity Hospital (n = 90) attended between 2011 and 2012 were retrospectively analyzed on the
basis of the availability of donor stimulator cells consisting of donor splenocytes in deceased-
donor transplants or of donor peripheral blood mononuclear cells (PBMC) in living-donor
transplants. The Bellvitge University Hospital ethics committee specifically approved the
study, and all patients gave written informed consent. None of the transplant recipients had
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received immunosuppression before providing PBMCs to perform the ELISPOT assay. The
pre-transplant ELISPOT result was not available to the clinicians before or after transplanta-
tion, and so had no influence on the choice of immunosuppression and clinical management
after the transplantation. The mean time of follow-up of this cohort was 21 months (range
6–48 months).
Main baseline demographic variables in all patients were collected at the time of enrollment
and included donor source and age, time on dialysis, number of human antigen leukocyte
(HLA) mismatches, number of previous transplants, presence of donor-specific circulating an-
tibodies by solid phase assays (Luminex1), cause of end-stage renal disease (ESRD) and recipi-
ent ethnicity (caucasian or otherwise). Furthermore, most relevant clinical variables associated
with clinical transplant outcome such as type of maintenance IS (CNI-based or not), steroid
withdrawal, use and type of induction therapy (T-cell depletion or not), delayed graft function
(DGF), six and twelve-month allograft function (both the estimated glomerular filtration rate,
eGFR, ml/min; and serum creatinine, μmol/L), CMV infection, biopsy-proven acute rejection
(BPAR), type (antibody-mediated, ABMR; or T-cell mediated, TCMR) and time of rejection
(early,<2 months or late,>2 months) were also pooled together for the analysis. DGF was de-
fined as the need for dialysis during the first week after transplantation. The use of either T-cell
depleting or monoclonal antibody induction therapy was based on the observed presumable
risk derived from the percentage of PRA and HLA mismatch data. CNI were used as mainte-
nance IS treatment in all but two patients who received mTor-inhibitors (Everolimus) as
main immunosuppression.
Estimated glomerular filtration rate (eGFR) was calculated using the simplified Modifica-
tion of Diet in Renal Disease equation (MDRD). All patients in the study showed a negative
pre-transplant Complement-dependent cytotoxic (CDC) cross-match test.
A second independent validation cohort of kidney transplant patients (n = 67) was used to
evaluate the predictive value of pre-transplant donor-specific T-cell alloreactivity on the advent
of early T-cell mediated allograft rejection. These set of patients were consecutively trans-
planted from November 2011 to October 2013. The clinical management of all these patients
was done irrespective of the pre-transplant donor-specific T-cell Elispot result, as the test was
not done.
HLA typing
Automated nucleotide sequencing was performed from genomic DNA by selective amplifica-
tion (PCR) of target exons from each locus for a particular allele. Loci sequenced included
HLA class I (A, B, and C) and II (DRB1/3/4/5 and DQA1/DQB1). Nucleotide sequencing was
done as previously described [19].
Alloantibody detection
Screening for circulating anti-HLA class I and II alloantibodies in peripheral blood was done
by FlowPRA screening beads (One-lambda Inc.). Antibody specificities of positive samples
were determined as previously described [20] using the LabScreen Single Antigen assay (One-
lambda Inc.).
IFN-γ ELISPOT assays and donor and recipient cell source
Donor-specific IFN-γ ELISPOT assays were done following recently described techniques
[18,21]. Peripheral blood samples were obtained in heparinized tubes from renal transplant re-
cipients before kidney transplantation. Donor cells were obtained from donor spleens or pe-
ripheral blood mononuclear cells (PBMCs) in deceased and living donors respectively. PBMCs
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and splenocytes were isolated by standard Ficoll density gradient centrifugation and were fro-
zen in liquid nitrogen and subsequently used for the IFN-γ ELISPOT assay. Deceased-donor
splenocytes were CD2-depleted (Easysep1Human CD2 Selection kit, StemCell, France) and
living-donor PBMCs were CD3-depleted (human CD3+ Cell Depletion Cocktail, RosetteSep1
kit, StemCell, France) and tested in triplicate wells with respective recipient PBMCs. A positive
d-s ELISPOT test was considered as25 IFN-γ spots/3x105 PBMC.
Renal allograft histology
Renal allograft biopsies were performed in patients undergoing acute clinical graft dysfunction.
All renal histologies were analyzed following the Banff ‘09 score, and histological analyses were
blindly evaluated.
Statistical analysis
All data are presented as mean ± sd. Groups were compared using the X2-test for categorical
variables and the one-way analysis of variance or Student’s t-test for normally distributed data
for quantitative variables, and the nonparametric Kruskal-Wallis or Mann-Whitney U-test for
non-normally distributed variables.
A sensitivity/specificity ROC curve analysis was done to determine the ELISPOT test value
for the prediction of the advent of early T-cell mediated acute rejection. Stepwise linear regres-
sion and binary logistic regression analysis were performed to determine the independent cor-
relation of several independent variables with the presence of early cellular acute rejection. The
statistical significance level was defined as p<0.05.
RESULTS
1. Main clinical and demographic variables associated with anti-donor
T-cell sensitization
The main baseline clinical and demographic variables were assessed among all patients for
their association with pre-transplant T-cell sensitization. As shown in Table 1, 37/90 (41.1%)
had detectable anti-donor alloreactivity pre-transplantation whereas 53/90 (58.9%) did not. No
differences were found regarding the number of previous transplants, cause of ESRD, ethnicity
or time on dialysis. No association was observed with the degree of pre-transplant humoral
sensitization of either donor or non-donor-specific anti-class I and II HLA antibodies. Interest-
ingly, anti-donor T-cell alloreactive patients tended to be older individuals receiving allografts
from older deceased donors with low HLA class I matching (Fig. 1). Regarding the validation
cohort, there were more T-cell sensitized patients than non T-cell sensitized, but were all of
them comparable regarding main clinical and immunological characteristics.
Two patients died during the first year; neither presented pre-formed donor-specific T-cell
sensitization. One died of a cardiac arrest nine months after transplantation and the other of
an opportunistic infection caused by pneumocystis juvencii. Three allografts were lost within
the first year, one due to a vein thrombosis, another due to unresolved urine leakage (both
were non-sensitized cellular transplant individuals), and a third in a highly T and B-cell sensi-
tized patient due to a severe BPAR (mixed ABMR and TCMR) who did not respond to inten-
sive rescue immunosuppressive treatment.
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2. Preformed anti-donor T-cell alloreactivity is associated with early
acute TCMR and worse allograft function after kidney transplantation
T-cell alloreactive and non-alloreactive patients were comparable in terms of main baseline
clinical variables such as the use and type of induction therapy, the choice of maintenance im-
munosuppression (principally based on CNI drugs, either Cyclosporine-A or Tacrolimus) as
well as regarding steroid withdrawal (Table 2). High pre-transplant anti-donor alloreactive pa-
tients showed higher incidence of DGF but similar incidence of CMV infection. When the
global incidence of BPAR was analyzed, no differences were found between T-cell alloreactive
Table 1. Patients’ demographic characteristics.
Training Set (n = 90) Validation Set (n = 67)
Baseline demographics Positive PRE-TX d-s
ELISPOT
(n = 37; 41%)
Negative PRE-TX d-s
ELISPOT
(n = 53; 59%)
P value Positive PRE-TX d-s
ELISPOT
(n = 46; 68.7%)
Negative PRE-TXd-s
ELISPOT
(n = 21; 31,3%)
P value
Donor age (years) 60.3±16 51±12.26 0.002 57.4±16.9 50.4±10.8 0.05
Recipient age (years) 55±14.6 48±14.20 0.02 52±15 54,1±9.7 0.50
Recipient gender (F) (%) 15 (40.5) 15 (28.3) 0.26 12 (26.1%) 7 (33.3) 0.77
Caucasian ethnicity (%) 33 (89.2) 51 (9796.2) 0.22 43 (95,6%) 20 (95,2%) 0,78
Cause of ESRD 0.25 0,36
- Unknown (%) 11 (29.7) 13 (24.5) 16 (35.6) 4 (18,2)
- Glomerular (%) 9 (35.9) 19 (32.4) 11 (24,4) 6 (27,3)
- Intersticial (%) 7 (18.9) 13 (24.5) 7 (15.2) 2 (9.5)
- Vascular (%) 4 (10.8) 2 (3.8) 5 (11,1) 6 (27,3)
- Diabetes (%) 4 (10.8) 6 (11.3) 2 (4.3) 0 (0)
Donor type (Living) (%) 10 (27) 40 (75.5) <0.001 9 (20,5%) 7 (31.8%) 0,36
Number of previous
transplants (<1TR/
>1TR) (%)
7(18.9) / 30(81.1) 6(11.3) / 47(88.7) 0.31 5(11) / 40(87) 2(9.5) / 19(90.5) 0.85
Dialysis duration (month) 45.2±45 42.3±46.7 0.76 34.4±19.7 36.1±30.6 0.83
Number Class I HLA
mismatch
2.83±1 2.4±1.15 0.06 2.89±0.68 2.19±1.37 0.04
Number Class II HLA
mismatch
1.16±0.5 1.16±0.76 0.95 1±0.57 0.95±0.67 0.76
HLA Class I Ab (Pos) (%) 4 (10.8) 5 (9.5) 0.9 2(4.3%) 3 (14.3%) 0,15
HLA ClassII Ab (Pos) (%) 6 (16.2) 9 (17) 0.9 5(10.9%) 2 (9.5%) 0,87
DSA (Pos) (%) 2 (5.4) 4 (7.5) 0.9 0 (0) 3 (13,6) 0.01
- HLA ClassI DSA (%) 0(0) 1 (11.1) 0.4 0 (0) 2 (66.6) 0,03
- HLA ClassII DSA (%) 2 (33.3) 4 (44.4) 0.7 0 (0) 1 (33.3) 0,14
rATG/Bxmab/No
induction (%)
12(32.5) /22(59,5) / 3
(8)
14(26) / 29(55) / 10(19) 0.35 4(8,7) / 38(82,6) / 4(8,7) 6(28,6) / 12(57,1) / 3
(14,3)
0.07
CNI-IS (TAC) (%) 33 (89.2) 43 (84.3) 0.51 44 (95.7) 19 (90.5) 0.41
Steroid withdrawal (<4
weeks) (%)
4 (10.8) 13 (24.5) 0.10 18 (39.1) 12 (57.1) 0.19
d-s IFN-γ spots/
3x105PBMC
69.34±42.7 4.7±5.6 <0.001 97±65,4 12.4±15.6 <0.001
Variables associated with pre-transplant donor-speciﬁc T-cell allosensitization.
APKD, autosomic polycystic kidney disease; D, deceased; d-s, donor-speciﬁc; DSA, donor-speciﬁc antigen; ESRD, end stage renal disease; F, female;
HLA, human leukocyte antigen; L, living; M, male; Neg, negative; PBMCs, peripheral blood mononuclear cells; PreTX, pre-transplant; Ab, antibodies;
PRA, panel reactive antibodies; Pos, positive; TR, transplants.
doi:10.1371/journal.pone.0117618.t001
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and non-alloreactive recipients (Fig. 2); neither ABMR nor TCMR were associated with pre-
formed donor-specific T-cell alloreactivity. Similarly, no association was observed between
pre-transplant T-cell ELISPOT and either graft loss or patient death.
In order to establish whether any specific time frame could most likely distinguish all TCMR
events significantly associated with pre-transplant T-cell sensitization, a receiver-operating char-
acteristic (ROC) curve analysis was carried out taking into account all time-points of BPAR epi-
sodes and the pre-transplant ELISPOT data. Interestingly, the first eight weeks after transplant
proved to be the most accurate time frame for identifying TCMR episodes that were related to
the pre-transplant donor-specific T-cell immune response, with a notably high sensitivity and
specificity (sensitivity = 75%, specificity = 80%) (AUC = 0.701, p = 0.065) (Fig. 3). Now, using
this time-period as a binary variable, a significant association was obtained between the pre-
Fig 1. Pre-transplant d-s T-cell alloreactivity positively correlates with recipient age and with HLA class I mismatch. A. Correlation between pre-
transplant frequency of donor-specific IFN-γ T-cell spots and recipient age (years) (R = 0.349, p = 0.001). B. Correlation between pre-transplant frequency of
donor-specific IFN-γ T-cell spots and class I HLA mismatches (R = 0.207, p = 0.05).
doi:10.1371/journal.pone.0117618.g001
Table 2. Impact of pre-transplant d-s T-cell allosensitization on allograft outcome.
Main clinical events
(N = 90)
Positive PreTX d-s T-cell
ELISPOT (n = 37; 41%)
Negative PreTX d-s T-cell
ELISPOT (n = 53; 59%)
p-value
DGF (yes/no) (%) 16 (43.2) / 21 (56.8) 12 (22.6) / 41 (77.4) 0.03
CMV infection (yes/
no) (%)
3 (8.1) / 34 (91.9) 8 (15.19) / 45 (84.9) 0.31
BPAR (yes/no) (%) 13 (35.1) / 24 (64.9) 14 (26.4) / 39 (73.6) 0.37
- Type (TCMR,
ABMR) (%)
11 (84.6) / 2 (15.4) 11 (78.5) / 3 (21.5) 0.56
- Time BPAR (<2mo/
>2mo) (%)
12 (92.3) / 1 (7.7) 6 (57.1) / 8 (42.9) 0.01
- Early TCMR (yes/no)
(%)
10 (27) / 27 (73) 5 (9.4) / 48 (90.6) 0.02
Graft loss (yes/no) (%) 1 (2.7) / 36 (97.3) 4 (7.6) / 49 (92.5) 0.32
Exitus (yes/no) (%) 0 (0) / 37 (100) 2 (3,8) / 51 (96,2) 0,23
PreTX: pre-transplant; BPAR, biopsy-proven acute rejection; CMV, cytomegalovirus; DGF, delayed graft
function; TCMR, T-cell mediated rejection; ABMR, antibody-mediated rejection.
doi:10.1371/journal.pone.0117618.t002
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transplant anti-donor T-cell sensitization and the occurrence of early TCMR, but it did not influ-
ence the occurrence of other rejection events (p = 0.022) (Fig. 2).
Even though pre-transplant anti-donor alloreactive patients showed worse 6 and 12-month
allograft function, these values were probably influenced by the significant higher donor age of
alloreactive transplant recipients as compared to non-alloreactive recipients (data not shown).
Nonetheless, a numerically worse allograft function was consistently observed among pre-
transplant alloreactive patients when stratified both by type of kidney transplant (living or de-
ceased donors) as well as by donor age (older or younger than 50 years old) (data not shown).
3. Young, highly pre-transplant T-cell alloreactive recipients show
particularly high risk of early TCMR after kidney transplantation
Since pre-transplant T-cell sensitization correlated positively with both recipient and donor ages
and are matched for transplant selection, we were particularly interested in determining whether
recipient age and pre-transplant cellular sensitization could influence the risk of early TCMR.
Therefore, we stratified recipient age as a binary variable (below or above 50 years), and evaluated
the risk of early TCMR depending on the pre-transplant ELISPOT test (R<50/ELSPOT- (n = 30);
R<50/ELSPOT+ (n = 14); R>50/ELSPOT- (n = 23) and R>50/ELSPOT+ (n = 23). As shown
in Fig. 4, a significantly higher incidence of early TCMR was observed among young highly
alloreactive individuals as compared to all other groups (R<50/ELSPOT- (3/15, 20%);
R<50/ELSPOT+ (6/15, 40%); R>50/ELSPOT- (2/15, 13.3%) and R>50/ELSPOT+ (4/15, 26.7%);
p = 0.03). This data was further confirmed when we put all patients of the discovery and predic-
tion set together (n = 157) (R<50/ELSPOT- (3/24, 12.5%); R<50/ELSPOT+ (10/24, 41%);
R>50/ELSPOT- (3/24, 12.5%) and R>50/ELSPOT+ (8/24, 33%); p = 0.05).
Fig 2. Pre-transplant d-s T-cell alloreactivity and early TCMR.No differences between preformed donor-
specific T-cell alloreactive responses and incidence of all types of BPAR were observed. Nevertheless,
kidney transplant patients developing early TCMR (< 2 months after transplantation) showed significantly
higher preformed donor-specific T-cell sensitization than those that did not (10/37;27% vs 5/53;9.4%,
p = 0.028). Red dots represent pre-transplant T-cell alloreactive kidney transplant patients developing
early TCMR.
doi:10.1371/journal.pone.0117618.g002
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4. T-cell depletion provides protection against early TCMR in highly
donor-specific T-cell alloreactive patients
Whether the use and type of induction therapy could impact on preformed highly alloreactive
anti-donor T-cell frequency was further evaluated. While the use of any type of induction thera-
py did not discriminate those patients developing any kind of BPAR (data not shown, p>0.05),
patients receiving T-cell depletion with rATG showed a significantly lower incidence of early
TCMR as compared to those that did not (1/26; 3,8% vs 14/64; 22%, respectively, p = 0.038)
(Fig. 5a). Furthermore, when only highly donor-specific alloreactive patients were analyzed in re-
lation to their type of induction therapy, eight out of 22 (36.4%) patients receiving anti-IL2R
(basiliximab) developed early TCMR, compared with only one out of 12 (8.3%) patients receiv-
ing rATG (0.07) (Fig. 5b). Of note, no protective effect by rATG was observed when non T-cell
alloreactive transplant patients were evaluated (4/38; 10.5%, non-sensitized patients not receiving
rATG experienced early TCMR vs 1/15, 6% developed early TCMR, p = NS).
Fig 3. Receiver operating characteristic (ROC) curve estimating the most likely time-frame of TCMR
associated with pre-transplant T-cell sensitization. Positive pre-transplant T-cell sensitization was a
highly sensitive and specific predictor of the advent of TCMR during the first 8 weeks (1.65 months) after
transplantation (AUC = 0.701; p = 0.065).
doi:10.1371/journal.pone.0117618.g003
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Fig 4. Incidence of early TCMR is higher within young T-cell alloreactive transplant recipients than in
elderly patients. Pre-transplant T-cell alloreactive individuals younger than 50 years old (R<50/ELISPOT+)
showed significantly higher incidence of early TCMR than young patients with a negative T-cell ELISPOT
(R<50/ELISPOT-) and elderly patients with either a positive (R>50/ELISPOT+) or negative pre-transplant
ELISPOT (R>50/ELISPOT-), (6/15;40%, 3/15;20%, 4/15;26.7%, 2/15;13.3%, respectively, p = 0.030).
Statistically significant differences were found between alloreactive individuals below 50 (R<50/ELISPOT+)
and non-alloreactive patients pre-transplantation [(R<50/ELISPOT-) and (R>50/ELISPOT-)] (p = 0.012 and
p = 0.014 respectively). A trend toward a significant difference was observed between patients under 50 and
elderly alloreactive patients (p = 0.091).
doi:10.1371/journal.pone.0117618.g004
Fig 5. T-cell depletion induction therapy provides protection against early TCMR. 5a. Patients receiving T-cell depletion as induction therapy showed
significantly lower incidence of early TCMR [3.8% (1/26) vs 22% (14/64) p = 0.038] than those that did not.5b. Incidence of early TCMR in anti-donor T-cell
sensitized patients receiving either anti-IL2 receptor blockade or rATG. A higher incidence of early TCMRwas observed among highly T-cell sensitized
patients receiving anti-IL2 receptor blockade than in patients receiving rATG [36.4% (8/22) and 8% (1/12); p = 0.07 respectively].
doi:10.1371/journal.pone.0117618.g005
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5. Absence of Pre-transplant d-s T-cell alloreactivity as a significant
protective variable for developing early TCMR
The most relevant clinical variables influencing the outcome of early TCMR (ethnicity, cold is-
chemia time, use of T-cell depletion, number of HLA mismatches, the advent of DGF, type of
donor as well as pre-transplant T-cell sensitization) were assessed with univariate and multi-
variate Cox regression analysis. Although non-caucasian ethnicity, longer ischemia time,
non-use of T-cell depletion and a positive pre-transplant ELISPOT were associated with an in-
creased risk of early TCMR, only the presence of baseline anti-donor T-cell sensitization and
non-use of T-cell depletion as induction therapy were significant independent correlates of risk
for early TCMR (Table 3).
6. Verification of pre-transplant anti-donor T-cell sensitization as a risk
factor for TCMR in a new cohort of kidney transplant patients
The impact of preformed donor-specific T-cell alloreactivity was validated in a second inde-
pendent cohort of kidney transplant patients with similar baseline clinical and immunological
characteristics. As shown in Table 4, although a rather low specificity and positive predictive
value was obtained, a high sensitivity and negative predictive value (88.9% and 95.2%, respec-
tively) was observed for the prediction of early TCMR (Table 4). Similarly to the training set,
highly alloreactive patients receiving T-cell depletion as induction therapy showed lower inci-
dence of TCMR as compared to those receiving either basiliximab or no induction therapy
(0/4 (0%) vs 12/38 (31,6%) vs 1/4 (25%), p = 0.06, respectively).
Table 3. Univariate and step-wise multivariate analyses of variables predicting early T-cell mediated rejection (TCMR).
Variables predicting Early TCMR (N = 90) Univariate analysis Multivariate analysis
RR CI 95% p RR CI 95% p
Caucasic ethnicity 6 1.082–33.274 0.04 0.2 0.021–1.960 0.16
Cold ischemia time (hours) 1.06 1.001–1.139 0.04 1.04 0.971–1.129 0.23
PreTX d-s IFN-γ ELISPOT (negative) 0,28 0.087–0.908 0.03 0.23 0.061–0.891 0.03
rATG induction 0,14 0.018–1.001 0.05 7.45 0.819–67.74 0.07
HLA mismatch (3) 0,31 0.083–1.221 0.09 0.18 0.028–1.227 0.08
DGF (yes) 0,44 0.143–1.380 0.16 2.38 0.34–16.74 0.38
Donor (Living) 3.00 0.932–9.653 0.06 0.01 0.001–2.30 0.1
CI, conﬁdence interval; DGF, delayed graft function; rATG, rat anti-thymocyte globulin;
RR, relative risk.
doi:10.1371/journal.pone.0117618.t003
Table 4. Predictive value of IFN-γ ELISPOT assay for early TCMR in an independent validation cohort.
Predictive value
Variable Sensitivity Speciﬁcity NPV PPV
PreTX d-s IFN-γ ELISPOT (25 IFN-γ spots /3×105 PBMC) 88.9% 62.5% 95.2% 40%
NPV, Negative predictive value; PreTX, pre-transplant; Pos, Positive; Neg, Negative.
doi:10.1371/journal.pone.0117618.t004
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DISCUSSION
In this study, we show that high frequencies of donor-specific alloreactive memory/effector
T cell responses before kidney transplantation is frequent among patients waiting for a kidney
allograft. Furthermore, we report for the first time that this preformed anti-donor T-cell sensi-
tization seems to have a direct negative impact on kidney allograft outcome by favoring TCMR
during the early period of time after transplantation, especially among highly T-cell sensitized
individuals against donor antigens and patients not receiving T-cell induction therapy. Of
note, this observation was further validated in a subsequent independent cohort of kidney
transplant patients with high sensitivity and negative predictive value.
Unlike acute antibody-mediated rejection (ABMR), TCMR remains an unpredictable pro-
cess in clinical practice since no accurate immune monitoring is currently done. However, in
recent years, a strong deleterious association has been observed between the presence of allor-
eactive memory T cells and clinical and also subclinical immune-mediated allograft injury or
allograft dysfunction in humans [12,13,22,23]. In this study, using the highly sensitive IFN-γ
ELISPOT assay, we emphasize that these immune-mediated events driven by preformed
donor-specific memory T-cell clones may not be predictable on the basis of epidemiological
backgrounds and may occur during the first weeks after transplantation. This is significant
since it suggests that delayed clinical or subclinical TCMR might be driven by either persistent
or rather, by de novo naïve T-cell activation, potentially reflecting insufficient immunosuppres-
sive exposure. In fact, in the multivariate analysis performed, the presence of high frequencies
of circulating donor-specific memory/effector T cells prior to transplant surgery was shown to
be an independent predictor of early TCMR, but not of all the immune-mediated clinical
events occurring later on. A plausible explanation of the relatively frequent detection of anti-
HLA cellular alloreactivity before kidney transplantation may be heterologous immunity, in
which T cells, initially primed against infectious agents and environmental antigens, cross-
react with allogeneic MHCmolecules [24,25]. Nevertheless, whether this or other mechanisms
are responsible for the presence of alloreactive memory T-cell responses in the absence of clear
allogeneic sensitization deserves further investigation.
A conclusion that can be drawn from our study is the importance of an optimal HLA
matching, especially within class I molecules between donor/recipient pairs in order to reduce
the chance that pre-formed memory T cells recognize donor alloantigens. Likewise, we recently
showed that the higher the number of HLA mismatches, the greater the frequency of donor-
specific memory T-cell responses, particularly among T-cell subsets primed by the direct path-
way of alloantigen presentation [26]. Even though not tested in our study, this finding and
those reported by others [12–17] suggest a role for both CD8+ and CD4+ memory T cells in
the anti-donor allogeneic immune response. Furthermore, as previously shown [18,26,27], the
pre-transplant anti-donor humoral allosensitization did not illustrate the allospecific cellular
immune response, emphasizing the importance of monitoring both effector mechanisms of
adaptive immunity before transplantation.
Even though older individuals showed increased frequencies of alloantigen-specific memory
T cells as compared to younger patients, younger T-cell alloreactive individuals seem to have a
more effective anti-donor effector immune response, as shown by the significantly higher inci-
dence of early TCMR particularly among younger alloreactive T-cell sensitized patients.
A plausible explanation is that although aged recipients exhibit higher numbers of memory
T cells with a broader antigen repertoire, these cells have a significantly poorer capacity to
mount effective recall effector responses compared with young memory/effector T cells
[28–30]. Interestingly, Hricik and colleagues [31] recently reported the increased risk of TCMR
and poorer graft function in patients receiving kidney allografts from older deceased donors,
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suggesting that the more inflammatorymilieu triggered in these grafts could facilitate a much
more effective effector T-cell response among T-cell sensitized individuals due to the higher
immunogenicity. In our study, although a similar higher T-cell sensitization was found among
individuals receiving older allografts, the most relevant variable influencing the outcome was
recipient’s age. This observation stresses the fact that transplant rejection is much more likely
to happen in highly T-cell sensitized younger individuals, whereas in older sensitized trans-
plant patients it would be facilitated if receiving highly immunogenic tissues from
older donors.
An important issue still under debate in clinical kidney transplantation is the choice and
type of induction therapy. In our study we found that the use of T-cell depletion as induction
therapy with rATG, in combination with CNI drugs, seemed to provide significantly better
protection for T-cell sensitized patients against developing TCMR than the use of anti-IL2 re-
ceptor monoclonal antibodies or no induction therapy. Indeed, we found a significant reduc-
tion of early TCMR among highly T-cell sensitized patients receiving rATG as compared to
transplant recipients using other type of induction treatment or no induction, whereas the use
of rATG did not provide any benefit as compared to other induction treatments when given in
non T-cell alloreactive individuals thus, suggesting the usefulness of this assay to individualize
the use of such aggressive induction therapy. This finding is in fact in line with previous reports
from others and us [18,32,33] advocating the use of induction therapy, particularly T-cell de-
pletion, to prevent post-transplant T-cell mediated rejection among highly T-cell
sensitized individuals.
The new observations reported in this work underline the high interest of this assay for
being implemented in clinical practice as it provides crucial information to transplant clini-
cians not currently available; on the one hand, the likelihood of T-cell mediated rejection in the
very early phases after transplantation that may not be inferred with patients’ baseline clinical
background on the other, help further refine decision-making regarding the use of T-cell deple-
tion as induction therapy, particularly among the most fragile transplant population, that is in
the older range of age, in whom in absence of humoral sensitization, this potent immunosup-
pression could be safely avoided.
A main limitation of this study is its retrospective nature. However, the multivariate analysis
performed, together with the results obtained, which corroborate those of some previous re-
ports, strengthen our observations and should alert the transplant community to the urgent
need to perform prospective, observational studies as well as interventional trials to test
our results.
The high sensitivitiy and particularly high negative predictive value of the ELISPOT test for
early TCMR is of great relevance due to its capacity to rule out the disease. Therefore, patients
with no evidence of T-cell sensitization would be suitable candidates to enroll in such clinical
trials, which should ideally be conducted under the auspices of international
collaborative networks.
CONCLUSIONS
High levels of donor-specific alloreactive memory T cells may be relatively frequent prior to
transplantation, despite the absence of any clinically recognizable sensitizing events. They may
directly facilitate the advent of TCMR early after transplantation, particularly in patients not
receiving T-cell depleting agents as induction therapy. Therefore, screening for anti-donor
T-cell sensitization should be seriously considered in kidney transplant patients. At this point,
prospective randomized trials are clearly warranted.
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